Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Indian Immunologicals kennel cough vaccine is a veterinary biologic developed to protect dogs against canine infectious respiratory disease (CIRD), commonly known as kennel cough or infectious tracheobronchitis. This contagious respiratory complex is caused by a variety of viral and bacterial pathogens. The vaccine is designed to stimulate active immunity against the primary causative agents, which typically include the bacterium *Bordetella bronchiseptica* and the canine parainfluenza virus, and may also include canine adenovirus type 2. By inducing the production of specific antibodies, the vaccine helps to prevent infection or significantly reduce the severity of clinical symptoms such as coughing and nasal discharge. It is part of Indian Immunologicals Limited's (IIL) companion animal vaccine portfolio and is reported to be in advanced stages of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Indian Immunologicals kennel cough vaccine.